Chen Zhang

Dr. Chen Zhang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
PLPian Liu
Pian Liu
SXShao-Hua Xie
Shao-Hua Xie
SHShaobo Hu
Shaobo Hu
XCXiang Cheng
Xiang Cheng
TGTianyi Gao
Tianyi Gao
ZSZifang Song
Zifang Song
Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States Age-Specific Sex Difference in the Incidence of Hepatocellular Carcinoma in the United States

1 January 2024 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
XHXiaoju Huang
Xiaoju Huang
MWMengmeng Wang
Mengmeng Wang
DZDan Zhang
Dan Zhang
CZChen Zhang
Chen Zhang
PLPian Liu
Pian Liu
Hepatocellular carcinoma is the prevailing malignant neoplasm affecting the liver, often diagnosed at an advanced stage and associated with an unfavorable overall prognosis. Sorafenib and Lenvatinib have emerged as first-line therapeutic drugs for advanced hepatocellular carcinoma, improving the prognosis for these patients. Nevertheless, the issue of tyrosine kinase inhibitor (TKI) resistance poses a substantial obstacle in the management of advanced hepatocellular carcinoma. The pathogenesis and advancement of hepatocellular carcinoma exhibit a close association with metabolic reprogramming, yet the attention given to lipid metabolism dysregulation in hepatocellular carcinoma development remains relatively restricted. This review summarizes the potential significance and research progress of lipid metabolism dysfunction in Sorafenib and Lenvatinib resistance in hepatocellular carcinoma. Targeting hepatocellular carcinoma lipid metabolism holds promising potential as an effective strategy to overcome hepatocellular carcinoma drug resistance in the future.

6 January 2022 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
PLPian Liu
Pian Liu
WZWei Zhou
Wei Zhou
LYLiu Yang
Liu Yang
CZChen Zhang
Chen Zhang

30 September 2025 in Oncogene
Verified
Journal Article
Closed access
PDF file
XCXiang Cheng
Xiang Cheng
MWMengmeng Wang
Mengmeng Wang
WLWei Li
Wei Li
BTBingzhang Tian
Bingzhang Tian
JZJing Zhang
Jing Zhang
PLPian Liu
Pian Liu

5 August 2025 in Journal of the Electrochemical Society
Verified
Journal Article
Closed access
PSPing Sun
Ping Sun
GWGuoliang Wang
Guoliang Wang
JXJianjun Xu
Jianjun Xu
WWWenqiang Wang
Wenqiang Wang
SHShaobo Hu
Shaobo Hu
CZChen Zhang
Chen Zhang
Integration of ultrasensitive photoelectrochemical (PEC) sensing with advanced computational analysis presents a novel approach for early cancer detection through circulating tumor DNA (ctDNA) methylation profiling. We report a synergistic platform combining BiOBr/WS2 heterojunction–based PEC sensor with attention–driven deep learning to decode cancer–specific methylation signatures. The BiOBr/WS2 composite, synthesized via a two–step hydrothermal process, demonstrated enhanced visible–light absorption and charge separation efficiency, achieving a 2.3–fold higher photocurrent response than pristine BiOBr. This sensor enabled ultrasensitive ctDNA detection with a linear range spanning six orders of magnitude (0.5 fM to 500 pM) and an ultralow detection limit of 0.05 fM. Deep learning revealed that attention mechanisms prioritized methylation loci in promoter regions and gene bodies, achieving 75% classification accuracy and a ROC AUC of 0.889. The model identified bidirectional methylation patterns, with 73% of high–weight CpG sites showing cancer–specific hypomethylation, challenging traditional hypermethylation–centric paradigms. The sensor exhibited exceptional selectivity against mismatched sequences, 95% signal stability over 7 days, and 97–103% recovery in human serum. By bridging nanomaterial–enhanced PEC transduction with context–aware methylation analysis, this work establishes robust framework for non–invasive cancer screening, emphasizing the critical role of epigenetic heterogeneity in early intervention strategies.

29 June 2026 in Cellular Oncology
Verified
Journal Article
Open access
PDF file
MWMengmeng Wang
Mengmeng Wang
LGLi Gu
Li Gu
RZRuijiang Zeng
Ruijiang Zeng
CZChen Zhang
Chen Zhang
JZJing Zhang
Jing Zhang
PLPian Liu
Pian Liu
Background The overall response rate to immune checkpoint inhibitors (ICIs) in HCC patients remains low. It has been reported that ITGB5 correlate with the immune infiltration of tumors. Our previous study showed that ITGB5 reduces HCC cell sensitivity to TKIs. However, the role of ITGB5 in HCC immunity remains unclear. Methods The mRNA and protein expression of ITGB5, SETDB1, LATS2 and PD-L1 in hepatocellular carcinoma cells and tissues were determined by RT-qPCR, Western Blot and Immunofluorescence. PD-L1 positive cells were analyzed by flow cytometry. The relationship between ITGB5 expression and immune cell infiltration was investigated by applying TIMER database. The effects of ITGB5 on the immune response and immunotherapy of hepatocellular carcinoma were determined by constructing a spontaneous tumor model of hepatocellular carcinoma and a subcutaneous tumor model in mice. Results ITGB5 promotes immune escape in HCC by activating PD-L1 expression, a target gene of the Hippo signaling pathway, through the SETDB1-LATS2 axis. ITGB5 reduces the susceptibility of HCC to immunotherapy. Importantly, ITGB5 knockdown enhanced the efficacy of PD-1 therapy in mice harboring HCC. Conclusions ITGB5 plays an important role in the immune response of hepatocellular carcinoma. ITGB5 may serve as a biomarker for evaluating immunotherapy efficacy and represent a promising therapeutic target for HCC treatment, either alone or in combination with anti-PD-1 antibodies. Graphical Abstract